AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.38.
AVEO has been the topic of a number of recent research reports. BidaskClub downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. initiated coverage on AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, B. Riley initiated coverage on AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price on the stock.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) opened at $3.03 on Thursday. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. The stock has a market capitalization of $358.47, a PE ratio of -4.27 and a beta of 1.30. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $4.24.
Several large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. acquired a new stake in shares of AVEO Pharmaceuticals in the third quarter valued at about $164,000. Essex Investment Management Co. LLC increased its position in AVEO Pharmaceuticals by 34.1% during the fourth quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock worth $564,000 after buying an additional 51,384 shares during the last quarter. Rehmann Capital Advisory Group acquired a new position in AVEO Pharmaceuticals during the third quarter worth approximately $193,000. OxFORD Asset Management LLP acquired a new position in AVEO Pharmaceuticals during the third quarter worth approximately $228,000. Finally, California Public Employees Retirement System increased its position in AVEO Pharmaceuticals by 360.6% during the fourth quarter. California Public Employees Retirement System now owns 153,845 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 120,445 shares during the last quarter. 50.96% of the stock is currently owned by institutional investors and hedge funds.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.